Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million)
Details : The new capital, alongside company's recently announced collaboration with Eisai supports lead small molecule programs targeting amyloid-β and α-synuclein, with first clinical candidate for amyloid-β in Q1 2021.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 25, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will use Wren’s network kinetics drug discovery platform, alongside Eisai’s extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 30, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
